About
The deal doesn’t shift in the boardroom. It shifts in the data room.
How life sciences executives are getting the best deal in M&A or raising capital without sacrificing leverage to the buyer by assuming the data was “good enough.”
Most life sciences executives believe their biggest transaction risks are clinical, regulatory, or financial.
Increasingly, they’re data-related not because the data is wrong but because investors and buyers can’t trust it.
A company can spend years building value, only to watch confidence erode when diligence uncovers data gaps, inconsistencies, compliance concerns, or information that can’t be validated.
The result isn’t usually a failed deal, but a lower valuation, reduced leverage for you, tougher negotiations, and unexpected delays.
The challenge is that most organizations don’t discover these risks until investors start asking questions they can’t answer confidently.
Join Ale Brown, Founder & CEO of Kirke Management Consulting and former Head of IT for Johnson & Johnson’s Diabetes division, for a practical 30-minute webinar where you’ll learn:
The questions investors and acquirers ask that expose data risks
- How hidden data risks impact valuation, deal terms, and investor confidence
- The warning signs your organization may not be as transaction-ready as you think
- Practical steps to reduce risk before diligence begins
The most expensive data issues are rarely the ones you know about, they’re the ones discovered by the buyer first.
